3/26
08:13 pm
cmrx
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 [Yahoo! Finance]
Low
Report
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 [Yahoo! Finance]
3/23
02:05 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/21
06:00 am
cmrx
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
Low
Report
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
3/17
12:45 pm
cmrx
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of Shareholders
3/15
02:05 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/11
03:05 pm
cmrx
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
3/11
02:20 pm
cmrx
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm
Low
Report
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm
3/10
10:33 pm
cmrx
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Low
Report
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
3/7
04:01 pm
cmrx
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/7
07:48 am
cmrx
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
Low
Report
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
3/7
06:18 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) was upgraded by analysts at Jones Trading to a "hold" rating.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) was upgraded by analysts at Jones Trading to a "hold" rating.
3/7
06:16 am
cmrx
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio [Yahoo! Finance]
Low
Report
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio [Yahoo! Finance]
3/7
12:47 am
cmrx
Jazz Pharmaceuticals bids for Chimerix in $935m deal [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals bids for Chimerix in $935m deal [Yahoo! Finance]
3/6
04:19 pm
cmrx
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More [Yahoo! Finance]
Low
Report
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More [Yahoo! Finance]
3/5
05:00 pm
cmrx
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
Neutral
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
3/5
04:55 pm
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "hold" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $8.50 price target on the stock, down previously from $10.00.
Neutral
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "hold" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $8.50 price target on the stock, down previously from $10.00.
3/5
01:37 pm
cmrx
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
3/5
12:27 pm
cmrx
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
Low
Report
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
3/5
12:18 pm
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $8.55 price target on the stock, up previously from $7.00.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $8.55 price target on the stock, up previously from $7.00.
3/5
11:57 am
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $8.55 price target on the stock, down previously from $11.00.
Low
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $8.55 price target on the stock, down previously from $11.00.
3/5
11:20 am
cmrx
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
3/5
07:54 am
cmrx
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Low
Report
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
3/5
07:00 am
cmrx
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
High
Report
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
3/4
02:19 pm
cmrx
Dopamine Receptor Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight [Yahoo! Finance]
Medium
Report
Dopamine Receptor Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight [Yahoo! Finance]
2/18
08:25 pm
cmrx
Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, up previously from $6.00.
Medium
Report
Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, up previously from $6.00.